Mnemo Therapeutics, a Paris, France-based biotechnology company developing cell therapies using a novel target identification engine, more potent T cells and manufacturing, completed a US$ 90M Series A financing.
Investors: The funding round was led by Casdin Capital, returning investor Sofinnova Partners, and an undisclosed investor, with participation from Redmile, Emerson Collective and Alexandria Venture Investments.
Purpose of the funding: The company seeks to utilize the funds for setting the pace for advancement of the EnfiniT targeting and future generation chimeric antigen receptors (CAR) T cell therapy platform amalgamating research from Institut Curie and Memorial Sloan Kettering Cancer Center (MSK).
About Mnemo Therapeutics
Mnemo Therapeutics, led by Alain Maiore, is a biotechnology company centred on modernizing cell therapies that create accessible cures. With its EnfiniT platform, a drug discovery engine, Mnemo executes a new, blended approach to cell therapy through accurate recognition of a new category of antigens with target specificity and the capacity to systematically reprogram T cells to enhance their memory phenotype, as well as refine their engineering. The firm believes that its approach can overcome the limitations of current CAR T-cell therapies and improve outcomes for patients with solid tumours and blood cancers.
What the Chairman of Board of Directors has to say: “Mnemo has made revolutionary advances in cell therapy research with a professional, passionate team of leaders effectively led by Alain, strongly connecting the leading minds in CAR T across the world. Mnemo can substantially enhance cell therapy and enable it to attain its full potential to confront tumours and fight incurable cancers.”- Dieter Weinand, Chairman of the Mnemo Board of Directors.
What the Investors have to say: “Our faith in Mnemo’s peculiar approach to cell therapy impelled us to lead the seed round in 2019. Now, more than ever, we are assertive in its ability to deliver an exceptional treatment standard across various solid tumours and blood cancers, with the potential to affect other devastating diseases. We are exhilarated to greet a powerful pool of international investors who now connect with us to bolster the power and potential of Mnemo’s groundbreaking technology.”- Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners. “We are thrilled to be associated with the Mnemo team as they crucially modernize the field of CAR T and flatten the mortality curve on hard-to-treat cancers.”- Eli Casdin, Founder and Chief Investment Officer of Casdin Capital.
For more extensive analysis and Market Intelligence reports feel free to approach us or visit our website: Venture Capital Market Intelligence Reports | VCBay.
We try our best to fact check and bring the best, well-researched and non-plagiarized content to you. Please let us know
-if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback and thank you for stopping by!
Next Article
[…] Next Article […]